EUCTR2016-001127-32-ES进行中（未招募）1 期
A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer’s Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 306
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Able to understand and provide signed informed consent, and must be able to sign and date an appropriate Health Insurance Portability and Accountability
- •Act (HIPAA) authorization form or subject privacy form, if appropriate.
- •- from the subject, if the subject is deemed competent to provide
- •informed consent
- •- from the subject’s legally authorized representative with the subject’s
- •assent, if the subject is deemed not competent to provide informed
- •- from the subject’s partner/caregiver during the conduct of the study
- •2. Male or female, 50 years of age or older
- •3. Has a diagnosis of probable AD according to the National Institute on Aging-Alzheimer’s Association (NIA-AA) guidelines
- •4. Meets criteria for agitation according to the International Psychogeriatric Association (IPA) guidelines
- •5. Has an MRI or CT scan (brain imaging) taken during or subsequent to diagnosis of AD, or during the screening period (prior to Baseline)
- •6. Has a Mini-Mental State Examination (MMSE) score of 5 to 26 (inclusive) at Screening
- •7. Has agitation/aggression defined as Neuropsychiatric Inventory
- •(NPI)-agitation/aggression subscore of =4 at both the Screening and Baseline visits with:
- •- severity score of =2, and
- •- frequency score of =2
- •8. Lives at home or in an assisted living facility. Subjects must have been at their current location for at least 3 weeks prior to Screening and plan to remain at the same location for the duration of the trial.
- •9. Has a designated study partner/caregiver (e.g., relative, housemate, close
- •personal friend, or professional caregiver) that is in contact with the subject at least 3 times a week on three separate days. The study partner/caregiver must:
- •- be willing and able to accompany the subject to all clinic visits,
- •- be capable of routinely monitoring and reporting study drug use,
- •- be regarded by the PI as sufficiently informed to report accurately on
- •these areas of the subject’s behavioral and functional status.
- •10. Both subject and study partner/caregiver are fluent in and able to read the local language in which study assessments are administered at the clinical site.
- •11. Both subject and study partner/caregiver are willing and able to participate in all scheduled evaluations and complete all required tests
- •12. If taking antidepressants, has been on a stable dose for at least 4 weeks prior to the Baseline visit and should be expected to remain on a stable dose throughout the trial
- •13. If taking cholinesterase inhibitors and/or memantine, has been on a stable dose for at least 12 weeks prior to the Baseline visit and should be expected to remain on a stable dose throughout the trial
- •14. If female, must be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception (e.g., oral, intrauterine device [IUD;
- •diaphragm], injectable, transdermal or implantable contraception) or
- •abstinence, for at least one month prior to randomization, during the study, and one month following completion of the study.
- •Females of childbearing potential must have a negative serum human
- •chorionic gonadotropin (hCG) pregnancy test at Screening and a negative urine hCG pregnancy test at Baseline
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 76
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 230
排除标准
- •1. The agitation/aggression is attributable to concomitant medications, environmental conditions, substance abuse, or active medical or psychiatric condition
- •2. Has a history of major depressive disorder, recurrent, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition
- •(DSM-5) diagnosis and has had a major depressive active episode (within the past year) according to the DSM-5 criteria
- •3. Treatment with an antipsychotic medication within 2 weeks of Baseline visit or 5 half-lives, whichever is longer
- •4. Has brain abnormalities seen on an MRI or CT scan (brain imaging) taken
- •during or subsequent to diagnosis of AD, that can be attributed to diseases or processes other than AD, including but not limited to:
- •- multiple lacunar infarcts or evidence of a single prior infarct >1 cm3;
- •- intracranial mass lesion (including but not limited to meningioma
- •[>1 cm3 with evidence of peritumoral edema]); or
- •- glioma, vascular malformation, or macrohemorrhage.
- •5. Subject or study partner/caregiver has medical condition (e.g., hearing, vision impairments) that would impair the ability to perform the study assessments
- •6. Using any of the medications prohibited or otherwise restricted (see
- •Protocol Section 5.7, Appendix B, and Appendix C)
- •7. Subject has had a myocardial infarction within the last 6 months prior to Screening
- •8. Subject has a known history or symptoms of long QT syndrome
- •9. Subject has a QRS interval <120 msec and whose Fridericia’s corrected QT interval (QTcF) is >460 msec at screening OR subject has a QRS interval =120 msec and QTcF is >480 msec at screening
- •10. Has clinically significant laboratory abnormalities that in the judgment of the Investigator would jeopardize the safe participation of the subject in the study
- •11. Has a history of a significant psychotic disorder prior to or concomitant with the diagnosis of Alzheimer’s disease including, but not limited to, schizophrenia or bipolar disorder
- •12. Current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic, or other medical disorder, including
- •cancer or malignancies that in the judgment of the Investigator would
- •jeopardize the safe participation of the subject in the study
- •13. Subject is bedridden or has any significant medical condition that is unstable and that would either:
- •- place the subject at undue risk from study drug or undergoing study
- •procedures; or
- •- interfere with the interpretation of safety or efficacy evaluations
- •performed during the course of the study
- •14. Has participated in or is participating in a clinical trial of any investigational drug, device, or intervention, and within 4 weeks (or five half-lives, whichever is longer) of the Baseline visit
- •15. Subject with sensitivity to pimavanserin or its excipients
- •16. Subject has previously participated in a clinical study with pimavanserin
- •17. Subject is judged by the Investigator or the Medical Monitor to be inappropriate for the study
研究者
相似试验
进行中（未招募）
1 期
The research study for patients with Alzheimer’s disease to examine the safety and efficacy of Pimavanserin for the treatment of symptoms of agitation and aggressioEUCTR2016-001127-32-GBACADIA Pharmaceuticals Inc.432
进行中（未招募）
不适用
A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients with Persistent Allergic Asthma BronchialeAdult Patients with Persistent Allergic AsthmaMedDRA version: 9.1Level: LLTClassification code 10001705Term: Allergic asthmaEUCTR2008-006927-29-DECytos Biotechnology AG60
进行中（未招募）
1 期
Evaluation of Mastic paint in the Treatment of nail disorders (Onycholysis, Onychomycosis, Onychorrhexis)OnychomycosisOnycholysisACTRN12614001238662Hawler Medical University75
已完成
2 期
To assess the clinical effect of QAW039 in non-atopic asthmatics taking low dose of inhaled corticosteroids (ICS) as background therapy.CTRI/2014/07/004743ovartis Healthcare Private Limited336
进行中（未招募）
1 期
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation TherapyBone Loss in Subjects Undergoing Androgen-Deprivation Therapy (ADT) for Non-metastatic Prostate CancerMedDRA version: 12.0Level: LLTClassification code 10065687Term: Bone lossEUCTR2009-012076-26-GRAmgen Inc760